A Phase 3 interventional study of Leuprorelin Acetate in Metastases, sponsored by UNICANCER. Active, not recruiting at 35 sites in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by UNICANCER · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Neoplasm Metastasis by UNICANCER — 8 open to participants now, 13 under way, 4 of them phase 3. Neoplasm Metastasis · UNICANCER.
Among the 25 studies in Neoplasm Metastasis by UNICANCER, this one has the largest planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2011, is one of 4 in phase 3, reaches primary completion later than 6 of the 12 other live ones, and was the 7th registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →8 of the 25 studies in Neoplasm Metastasis by UNICANCER are open now, in 1 country. Recruiting first, the newest first:
UNICANCER · Sites in France
Ages 12+
UNICANCER · Sites in France
Ages 18+
UNICANCER · Sites in France
Ages 18+
UNICANCER · Sites in France
Ages 18+
UNICANCER · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 700 is above the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 104 across the 22 interventional studies, 510 across the 1 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
UNICANCER is the lead sponsor of 219 studies on the registry; 52 are open to participants now.
4 of the studies in Neoplasm Metastasis by UNICANCER that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01442246Phase 3UNICANCEREvaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients. | 2027-09 |
| NCT05476796UNICANCEROxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer | 2026-12 |
| NCT06475352UNICANCERDose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme | 2027-04 |
| NCT06846346UNICANCERTesting Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Neoplasm Metastasis by UNICANCER, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PRINCIPAL OBJECTIVE: Evaluation of effectiveness in terms of survival without metastases to 10 years, of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of recurrence.
SECONDARY OBJECTIVE(S):
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients R0, N0 or Nx or N+ (≤ 2 nodes among nodes removed), M0 and with at least one of the following criteria:
Exclusion Criteria:
Presence of :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leuproreline acetate
Drug: Leuprorelin Acetate
Surveillance
Leuprorelin Acetate 45 mg, one injection every 6 months for 24 months
Also known as: Eligard®
The principal criterion is the evaluation of effectiveness in terms of survival without metastases to 10 years, of adjuvant treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy.
Time frame: The principal criterion will be evaluated 12 years after the inclusion of the first patient.
Started Jul 2011 (actual). Primary completion is estimated for Sep 2027, 194 months after the start.
Of 55 non-industry phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 108. This study's planned 194 months is above that.
Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide